These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35178375)

  • 1. Can the Profitability of Medical Enterprises Be Improved After Joining China's Centralized Drug Procurement? A Difference-in-Difference Design.
    Hua YF; Lu J; Bai B; Zhao HQ
    Front Public Health; 2021; 9():809453. PubMed ID: 35178375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of China's National Centralized Drug Procurement Policy on pharmaceutical enterprises' financial performance: a quasi-natural experimental study.
    Sun Z; Na X; Chu S
    Front Public Health; 2023; 11():1227102. PubMed ID: 38026347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of National Centralized Drug Procurement policy on chemical pharmaceutical enterprises' R&D investment: a difference-in-differences analysis in China.
    Li J; Zhang X; Wang R; Cao K; Wan L; Ren X; Ding J; Li W
    Front Public Health; 2024; 12():1402581. PubMed ID: 39011324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of centralized volume-based procurement of drugs on business performance of listed pharmaceutical enterprises.
    Ke Z; Zhang Y; Duan D
    Heliyon; 2024 Jun; 10(12):e33198. PubMed ID: 39021986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The change of drug utilization in China's public healthcare institutions under the "4 + 7" centralized drug procurement policy: Evidence from a natural experiment in China.
    Lu J; Long H; Shen Y; Wang J; Geng X; Yang Y; Mao Z; Li J
    Front Pharmacol; 2022; 13():923209. PubMed ID: 36081942
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of China's National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin.
    Zhao B; Wu J
    Int J Health Policy Manag; 2023; 12():7724. PubMed ID: 38618801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series.
    Long H; Yang Y; Geng X; Mao Z; Mao Z
    Front Pharmacol; 2022; 13():944540. PubMed ID: 35910351
    [No Abstract]   [Full Text] [Related]  

  • 8. Does China's national volume-based drug procurement policy promote or hinder pharmaceutical innovation?
    Li X; Xu J
    Front Pharmacol; 2024; 15():1392239. PubMed ID: 38994196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis.
    Wang N; Yang Y; Xu L; Mao Z; Cui D
    BMC Public Health; 2021 Oct; 21(1):1883. PubMed ID: 34663282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of '4+7' volume-based drug procurement on the use of policy-related original and generic drugs: a natural experimental study in China.
    Wang J; Yang Y; Xu L; Shen Y; Wen X; Mao L; Wang Q; Cui D; Mao Z
    BMJ Open; 2022 Mar; 12(3):e054346. PubMed ID: 35288385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of centralized band purchasing of pharmaceuticals on innovation of Chinese pharmaceutical firms: an empirical study based on double difference models.
    Chen X; Chen S; Wu Z; Wang S; Chen Y
    Front Public Health; 2024; 12():1406254. PubMed ID: 39035183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does China's centralized volume-based drug procurement policy facilitate the transition from imitation to innovation for listed pharmaceutical companies? Empirical tests based on double difference model.
    Gu Y; Zhuang Q
    Front Pharmacol; 2023; 14():1192423. PubMed ID: 37324496
    [No Abstract]   [Full Text] [Related]  

  • 13. The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis.
    Wang X; He X; Zhang P; Zhang M; Ma R; Dai R; Li X
    Int J Equity Health; 2023 Sep; 22(1):200. PubMed ID: 37770924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-examining the effect of carbon emission trading policy on improving the green innovation of China's enterprises.
    Yang S; Lu T; Huang T; Wang C
    Environ Sci Pollut Res Int; 2023 Jan; 30(3):7696-7717. PubMed ID: 36044137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Has the consistency evaluation policy of generic drugs promoted the innovation quality of Chinese pharmaceutical manufacturing industry? An empirical study based on the difference-in-differences model.
    Liu Q; Huang Z; Mao Z
    Front Public Health; 2023; 11():1265756. PubMed ID: 38106910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of Chinese volume-based procurement on pharmaceutical market concentration.
    Yang Y; Liu Y; Mao Z; Mao J; Jin Y
    Front Pharmacol; 2024; 15():1386533. PubMed ID: 38895618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tax preference, financing constraints and enterprise investment efficiency-Experience, of China's enterprises investment.
    Zhai L; Feng Y; Li F; Zhai L
    PLoS One; 2022; 17(9):e0274336. PubMed ID: 36137158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incentive effect of tax preferences towards the technological innovation of enterprises--Based on China's GEM listed companies.
    Ding L; Wu Y; Long J
    PLoS One; 2023; 18(4):e0282692. PubMed ID: 37058543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving access to medicines and beyond: the national volume-based procurement policy in China.
    Zhu Z; Wang Q; Sun Q; Lexchin J; Yang L
    BMJ Glob Health; 2023 Jul; 8(7):. PubMed ID: 37463786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of China's Low Centralized Medicine Procurement Prices on the Cost-Effectiveness of Statins for the Primary Prevention of Atherosclerotic Cardiovascular Disease.
    Wang M; Liu J; Bellows BK; Qi Y; Sun J; Liu J; Moran AE; Zhao D
    Glob Heart; 2020 Jun; 15(1):43. PubMed ID: 32923337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.